Case Report: Initial Management of ST-Elevation Myocardial Infarction Patients with Hypotension in the Emergency Unit of Merauke Regional General Hospital
Keywords:
Anteroseptal STEMI, Fibrinolysis, Streptokinase, Dobutamine, HypotensionAbstract
ST-elevation myocardial infarction (STEMI) is a cardiovascular emergency caused by acute coronary artery occlusion that requires immediate reperfusion therapy to limit infarct size and reduce mortality. In healthcare facilities with limited access to primary percutaneous coronary intervention (PCI), fibrinolytic therapy remains an important reperfusion strategy. A 71-year-old man presented to the emergency department with typical chest pain that had begun one hour before admission. The pain radiated to the left arm, left neck, and back and was accompanied by nausea, vomiting, and cold sweats. Electrocardiography (ECG) revealed ST-segment elevation in leads V1–V5, consistent with anteroseptal STEMI with an onset of less than 12 hours. Initial management included oxygen supplementation, dual antiplatelet therapy, anticoagulation, high-intensity statin therapy, intravenous nitrates, and fibrinolytic therapy with 1.5 million units of streptokinase. Ten minutes after fibrinolysis was initiated, the patient developed severe hypotension, with a blood pressure of 60/43 mmHg. Intravenous nitrate therapy was immediately discontinued, and dobutamine infusion was initiated. Following this intervention, the patient's blood pressure increased to 116/69 mmHg, accompanied by improved hemodynamic stability. Early diagnosis and prompt reperfusion therapy are essential in the management of anteroseptal STEMI. Fibrinolytic therapy remains an effective reperfusion option in healthcare facilities with limited access to primary PCI. Close monitoring for hemodynamic complications, particularly hypotension during treatment, is crucial to prevent progression to cardiogenic shock and improve patient outcomes.
References
Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2025;85(22):2135–2237. doi:10.1016/j.jacc.2024.11.009.
Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862. doi:10.1161/CIR.0000000000001309.
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191.
Timmis A, Kazakiewicz D, Townsend N, Huculeci R, Aboyans V, Vardas P. Global epidemiology of acute coronary syndromes. Nature Reviews Cardiology. 2023;20:778–788. doi:10.1038/s41569-023-00884-0.
Coughlan JJ, Ibanez B. Reperfusion in ST-elevation myocardial infarction: delays have dangerous ends. European Heart Journal. 2023;44(6):529–531. doi:10.1093/eurheartj/ehac723.
Kochan A, Lee T, Moghaddam N, et al. Reperfusion delays and outcomes among patients with ST-segment-elevation myocardial infarction with and without cardiogenic shock. Circulation: Cardiovascular Interventions. 2023;16(6):e012810. doi:10.1161/CIRCINTERVENTIONS.122.012810.
Bouyaddid S, et al. Pharmaco-invasive therapy: A continued role for fibrinolysis in the primary PCI era. Clinical and Applied Thrombosis/Hemostasis. 2023;29:10760296231221549. doi:10.1177/10760296231221549.
De Luca L, Mistrulli R, Scirpa R, Thiele H, De Luca G. Contemporary management of cardiogenic shock complicating acute myocardial infarction. Journal of Clinical Medicine. 2023;12(6):2184. doi:10.3390/jcm12062184.
Peters EJ, Ten Berg S, Bogerd M, et al. Characteristics, treatment strategies and outcome in cardiogenic shock complicating acute myocardial infarction: A contemporary Dutch cohort. Journal of Clinical Medicine. 2023;12(16):5221. doi:10.3390/jcm12165221.
Basir MB, Lemor A, Gorgis S, et al. Early utilization of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The National Cardiogenic Shock Initiative. Journal of the American Heart Association. 2023;12(23):e031401. doi:10.1161/JAHA.123.031401.
Vallabhajosyula S, Verghese D. Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock. ESC Heart Failure. 2021;8(3):2025–2035. doi:10.1002/ehf2.13281.
Podlesnikar T, Pizarro G, Fernández-Jiménez R, et al. Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance. 2020;22:44.
Johansson B, Nordlund D, Harnek J, et al. Anterior STEMI associated with decreased strain in remote cardiac myocardium. International Journal of Cardiovascular Imaging. 2021;37(6):1969–1978.
Saito Y, Tateishi K, Kobayashi Y. Clinical review of cardiogenic shock after acute myocardial infarction: Revascularization, mechanical circulatory support, and beyond. Circulation Reports. 2025;7(1):6–14. doi:10.1253/circrep.CR-24-0141.
Lüsebrink E, Binzenhöfer L, Adamo M, et al. Cardiogenic shock. The Lancet. 2024;404(10466):2006–2020. doi:10.1016/S0140-6736(24)01818-X.










